

George Church, a Harvard professor and a famed geroscientist, is also known as a serial entrepreneur who has co-founded dozens of biotech companies. While Church maintains that he’s involved in

Retro Biosciences, one of the hottest startups in the longevity field, was founded about five years ago by the tech entrepreneur Joe Betts-Lacroix with a $180 million investment from his

European scientists have created a GPT-based model that can predict the risk of more than a thousand diseases on par with single-disease tools and biomarker-based models [1]. Tell me the

The Arc Institute, a nonprofit research organization, has published a manuscript on its creation of Evo 2, an AI foundation model that is capable of both understanding and building full

Once confined to the realms of science fiction or relatively crude internet death calculators, AI-driven predictions about longevity are inching closer to reality. Questions about the accuracy and value of

Back in 2006, a website called “The Death Clock” appeared on the internet, with a promise to answer one of life’s greatest questions: “When will I die?” Since then, over

In Aging, researchers from Spain and Luxembourg have described the creation of Single-cell RNA-seq Investigation of Rejuvenation Agents and Longevity (SINGULAR), an atlas for cellular rejuvenation that describes how interventions

In a recent paper published in International Journal of Medical Sciences, researchers have described how they used artificial intelligence and machine learning tools to find mTOR-inhibiting molecules [1]. mTOR is

Research published today in Nature Aging has described a machine learning algorithm that finds senescent cell-removing drugs (senolytics) and compared the algorithm’s discoveries to existing compounds. A quest for effective

Scientists have compared doctor-written and chatbot-generated responses to healthcare-related questions, and the results don’t look good for Team Human [1]. Ask your doctor? Access to healthcare has been linked to

In March 2023, MIT Technology Review revealed that Sam Altman, the CEO of OpenAI (ChatGPT), was the mystery investor behind the $180 million investment into stealth startup Retro Biosciences, a

George Church, a Harvard professor and a famed geroscientist, is also known as a serial entrepreneur who has co-founded dozens of biotech companies. While Church maintains that he’s involved in them all, one company has been seeing an unusual amount of his attention: Lila Sciences, where

Retro Biosciences, one of the hottest startups in the longevity field, was founded about five years ago by the tech entrepreneur Joe Betts-Lacroix with a $180 million investment from his friend Sam Altman, the CEO of OpenAI. Despite its hefty war chest, the company initially pursued

European scientists have created a GPT-based model that can predict the risk of more than a thousand diseases on par with single-disease tools and biomarker-based models [1]. Tell me the future! For millennia, people have wanted to know what health events await them in the future.

The Arc Institute, a nonprofit research organization, has published a manuscript on its creation of Evo 2, an AI foundation model that is capable of both understanding and building full genomes of organisms. A new step in understanding biology The authors of this paper, a group

Once confined to the realms of science fiction or relatively crude internet death calculators, AI-driven predictions about longevity are inching closer to reality. Questions about the accuracy and value of these forecasts remain. In recent years, researchers and companies around the globe have been pursuing answers

Back in 2006, a website called “The Death Clock” appeared on the internet, with a promise to answer one of life’s greatest questions: “When will I die?” Since then, over 60 million people have used the site, which gives a somewhat grim countdown to the day

In Aging, researchers from Spain and Luxembourg have described the creation of Single-cell RNA-seq Investigation of Rejuvenation Agents and Longevity (SINGULAR), an atlas for cellular rejuvenation that describes how interventions affect individual cells. Computational biology might light up a better path These researchers begin this paper

In a recent paper published in International Journal of Medical Sciences, researchers have described how they used artificial intelligence and machine learning tools to find mTOR-inhibiting molecules [1]. mTOR is a common target for lifespan extension interventions The mechanistic target of rapamycin (mTOR) is a well-known

Research published today in Nature Aging has described a machine learning algorithm that finds senescent cell-removing drugs (senolytics) and compared the algorithm’s discoveries to existing compounds. A quest for effective therapeutics After covering familiar territory regarding senescent cells, this paper begins with a discussion of existing

Scientists have compared doctor-written and chatbot-generated responses to healthcare-related questions, and the results don’t look good for Team Human [1]. Ask your doctor? Access to healthcare has been linked to longer lifespan, and good healthcare often starts with a good initial consultation. A group of researchers,

In March 2023, MIT Technology Review revealed that Sam Altman, the CEO of OpenAI (ChatGPT), was the mystery investor behind the $180 million investment into stealth startup Retro Biosciences, a biotech company with the ambition of “adding 10 years to the human lifespan.” This investment marks